Clinical Trials
20 trialsNCT07630961 2026-06-05
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Novartis
Phase 1 Not yet recruiting
NCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05492682 2026-05-12
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase 1 Recruiting
NCT07297667 2026-05-12
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1 Not yet recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07261631 2026-04-28
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Phase 1 Recruiting
NCT07229313 2026-04-16
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Phase 1 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT03017573 2026-02-03
SCANDARE
Institut Curie
Phase NA Recruiting
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05827614 2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1 Active not recruiting
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT04725331 2025-11-21
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Phase 1/2 Terminated
NCT02936102 2025-11-14
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT07064018 2025-07-14
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
Phase 1/2 Recruiting
NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended